
Respiratory syncytial virus (RSV) spreads readily within families through close contact, respiratory droplets and contaminated surfaces, while the youngest infants face the greatest risk of severe illness, according to US household surveillance published in Clinical Infectious Diseases and guidance from the Centers for Disease Control and Prevention (CDC). A prospective US study conducted during 2022–2023 found 37 potential secondary infections after a household index case, with children frequently involved in transmission. The findings help distinguish how infection moves through a household from the separate question of which family members are most likely to need hospital care.
Children can introduce RSV into a household, but transmission does not always start with an older sibling
The virus infects the respiratory tract and can pass between household members when an infected person coughs or sneezes near someone else. It also spreads through direct contact, including kissing an infant’s face, and through hands that touch contaminated objects before touching the eyes, nose or mouth. The CDC notes that RSV survives for many hours on hard surfaces, including crib rails and tables, although survival varies with the environment.
A US prospective community-based study followed participants from June 2022 through May 2023 with at least weekly nasal swabs and surveys, regardless of symptoms. Researchers also used antibody testing and viral genome sequencing to investigate whether closely timed infections were consistent with transmission inside a household. RSV was detected in 310 participants across 200 households. The team identified 37 possible secondary infections occurring within 14 days of a separate index case, corresponding to an estimated 10% household-contact secondary infection proportion (95% confidence interval, 7%–14%).
The median age of index cases was 6 years, compared with 35 years for secondary cases. Among index cases with the relevant age data, 24 of 27 were between 6 months and 12 years old. Viral genetic similarity supported household spread when cases occurred close together, but even sequencing cannot prove precisely who infected whom in every family.
These findings address household transmission, rather than the effectiveness of the maternal vaccine and infant antibody prevention options available today.
Household transmission estimates vary considerably by study design
A separate prospective study in Zhejiang, China, published in the Journal of Infection in 2026, followed 179 households with a medically attended, laboratory-confirmed pediatric RSV case and assessed 542 household contacts. Researchers identified secondary infections in 218 contacts (40.2%) and in 110 households (61.5%). More than half of secondary infections were asymptomatic.
The 40.2% figure should not be interpreted as a universal probability of catching RSV from an infected family member. The Chinese study recruited families after a child sought medical care and used a different sampling and testing schedule from the US community cohort. The studies also involved different populations and epidemic periods. Both show that RSV can spread within households, but their numerical estimates cannot be directly compared as if they came from the same experiment.
Infected people can spread RSV before a cold is obvious
According to the CDC, people with RSV are usually contagious for 3–8 days and may begin spreading the virus 1–2 days before symptoms appear. Some infants and people with weakened immune systems can continue shedding virus for four weeks or longer, even after symptoms improve. Symptoms generally develop around 4–6 days after infection.
These overlapping periods make symptom-based precautions imperfect. A preschooler may bring home RSV from childcare before the family recognizes an illness; an adult may develop only mild cold symptoms. A lack of fever does not rule out RSV in a young infant.
When someone in the household is sick, reducing close face-to-face contact with a newborn, washing hands before handling the baby, cleaning high-touch surfaces and improving indoor air can reduce opportunities for viral spread. These measures lower risk but cannot guarantee that an infant will avoid infection.
The first months of life carry the greatest risk of severe disease
Nearly all children encounter RSV by their second birthday, but most infections do not require hospitalization. Risk is not evenly distributed across infancy. The CDC identifies very young infants as the group at highest risk, including babies who were born at term and have no underlying diagnosis. In a typical year, approximately 2–3 in every 100 infants younger than 3 months are hospitalized with RSV, according to the CDC.
Severe illness can develop when RSV infects the small airways and causes bronchiolitis, or when infection involves the lungs and causes pneumonia. Young infants have narrow airways and limited respiratory reserve. Premature birth, chronic lung disease, congenital heart disease, compromised immunity and certain neuromuscular disorders further increase vulnerability.
RSV may initially look like a routine cold. Infants can develop a runny nose and reduced feeding before cough or wheezing becomes apparent. In babies younger than 6 months, warning signs may include unusual irritability, reduced activity, poor feeding or apnea, which refers to pauses in breathing.
Difficulty breathing, inadequate fluid intake, pauses in breathing or worsening symptoms require prompt medical assessment. Severe breathing difficulty, blue or gray discoloration, or an infant who is difficult to wake warrants emergency care. The symptoms alone cannot identify the responsible virus, so a clinician may assess the child for RSV and other causes.
Protection against severe RSV disease now begins before many babies are exposed
US prevention recommendations provide two principal ways to protect infants against severe RSV disease: maternal vaccination during an eligible pregnancy or a long-acting monoclonal antibody given to the infant. Most infants do not need both. The CDC recommends Pfizer’s Abrysvo for eligible pregnant people at 32–36 weeks’ gestation during September through January in most of the United States. For qualifying babies entering their first RSV season, the infant antibody options are nirsevimab and clesrovimab.
The antibody approach delivers protection directly rather than asking the infant’s immune system to produce its own response. Eligibility depends on maternal vaccination status, the baby’s age, birth timing and specific risk factors. Families navigating these choices can consult our explanation of how nirsevimab and clesrovimab differ and our review of how long nirsevimab protection lasts.
Immunization is designed to prevent severe illness, not to make household hygiene unnecessary or to guarantee that RSV infection cannot occur. Seasonal timing also varies geographically. Clinicians can use current CDC and local public-health guidance to advise families whose babies are approaching their first RSV season.
The research cannot identify a single route of infection in every family
Household studies have important limitations. Repeated nasal sampling and viral sequencing can strengthen evidence that infections cluster in time and share a viral lineage, but virus introductions can occur outside the home and individual transmission events are rarely observed directly. Some infections are asymptomatic, and testing intervals can miss short periods of viral detection.
The US cohort preceded broad implementation of the newest infant RSV immunizations. The Chinese study selected households around medically attended pediatric cases, which may produce a different infection profile from a random sample of families. Neither study establishes that a particular cleaning routine or household practice prevents a specific percentage of infections.
With RSV season generally running from fall into winter in much of the United States, the evidence supports reducing exposure opportunities around newborns while prioritizing the immunizations recommended for their age and circumstances. The greatest clinical concern remains the first months of life, when even a previously healthy baby may develop significant lower respiratory tract disease.
References
- Cox SN, et al. Household Transmission and Genomic Diversity of Respiratory Syncytial Virus in the United States, 2022–2023. Clinical Infectious Diseases. 2025;81(6):1159–1169. DOI: 10.1093/cid/ciaf048.
- Household transmission dynamics of human respiratory syncytial virus in China: A multicentre epidemiological and molecular study. Journal of Infection. 2026;93(3):106834. DOI: 10.1016/j.jinf.2026.106834.
- Centers for Disease Control and Prevention. How RSV Spreads; RSV in Infants and Young Children; Immunizations to Protect Infants. Updated 2025–2026.